These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30359047)

  • 61. Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
    ESUB-MG Study Group
    BMC Fam Pract; 2016 Mar; 17():24. PubMed ID: 26931763
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
    Khan A; Khan Q; Kolb E
    J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Access to treatment for opioid use disorders: Medical student preparation.
    McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J
    Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Novo P; Campbell ANC; Greiner M; Lee JD; Rotrosen J; Nunes EV
    J Addict Med; 2023 Sep-Oct 01; 17(5):618-620. PubMed ID: 37788622
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
    Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
    BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The influence of anxiety sensitivity on opioid use disorder treatment outcomes.
    Baxley C; Weinstock J; Lustman PJ; Garner AA
    Exp Clin Psychopharmacol; 2019 Feb; 27(1):64-77. PubMed ID: 30080059
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
    Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
    Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.
    Nordmann S; Frauger E; Pauly V; Orléans V; Pradel V; Mallaret M; Thirion X; Micallef J
    Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):184-90. PubMed ID: 22109894
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
    Schottenfeld RS; Chawarski MC; Pakes JR; Pantalon MV; Carroll KM; Kosten TR
    Am J Psychiatry; 2005 Feb; 162(2):340-9. PubMed ID: 15677600
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Patient Perceptions of Integrating Meditation-based Interventions in Office-based Opioid Treatment with Buprenorphine: A Mixed-methods Survey.
    Tofighi B; Marini C; Lee JD; Garland EL
    J Addict Med; 2023 Sep-Oct 01; 17(5):517-520. PubMed ID: 37788602
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
    Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
    Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
    Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
    J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
    González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
    Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.
    Peck KR; Ochalek TA; Streck JM; Badger GJ; Sigmon SC
    Pain Med; 2021 May; 22(5):1205-1212. PubMed ID: 33585885
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.
    Bertz JW; Epstein DH; Reamer D; Kowalczyk WJ; Phillips KA; Kennedy AP; Jobes ML; Ward G; Plitnick BA; Figueiro MG; Rea MS; Preston KL
    J Subst Abuse Treat; 2019 Nov; 106():43-57. PubMed ID: 31540611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.